MetaCap

Bicycle Therapeutics (BCYC) vs Faeth Therapeutics (FTH)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Faeth Therapeutics (FTH) has outperformed Bicycle Therapeutics (BCYC) over the past year, losing 9.6% versus a loss of 54.1%. Over five years, BCYC leads with a -94.7% price change compared with -95.0% for FTH. Faeth Therapeutics is the larger company by market cap ($203.7 million vs $203.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BCYC-54.11%FTH-9.64%
+380%+153%-75%
Nov 21, 20251 yearNov 20, 2026
BCYC-95.01%FTH-95.34%
+10%-46%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BCYC versus FTH key metrics
MetricBCYCFTH
Share price$2.90$7.88
Market cap$203.27M$203.65M
1-day change-4.92%-9.32%
YTD return-59.04%-26.15%
1-year return-54.11%-9.64%
5-year return-94.69%-94.96%
EPS (TTM)$-2.03$-22.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$72.59M—
Revenue growth (YoY)+105.77%—
Net income (latest FY)$-218.96M$-21.09M
Operating margin-340.38%—
Net margin-301.66%—
52-week high$7.83$42.14
52-week low$2.85$7.45
Distance from 52-week high-62.96%-81.30%
Analyst consensusbuystrong_buy
Avg. price target upside+216.21%+612.56%
Average volume444.72K500.25K
Shares outstanding50.66M25.84M
Employees28829
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FTH has outperformed BCYC by 44.5 percentage points over the past year.

About Bicycle Therapeutics

BCYC stock →

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.

Health Care · Biotechnology: Pharmaceutical Preparations · 288 employees

About Faeth Therapeutics

FTH stock →

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

BCYC vs FTH FAQ

Which is bigger, Bicycle Therapeutics or Faeth Therapeutics?

Faeth Therapeutics (FTH) is larger, with a market capitalization of $203.65M compared with $203.27M for Bicycle Therapeutics (BCYC).

Which stock has performed better over the past year, BCYC or FTH?

FTH returned -9.64% over the past 12 months, compared with -54.11% for BCYC (price return, excluding dividends). Past performance does not predict future results.

Are Bicycle Therapeutics and Faeth Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons